Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

Opinion
Video

Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.

Video content above is prompted by the following:

1. 2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
a. Discuss the treatment options with strong recommendations and high certainty of evidence.
i. Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
ii. JAK inhibitors: abrocitinib, baricitinib, upadacitinib

Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Brittany Bruggeman, MD
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.